Regeneron offers a positive look at the first cut of its Covid-19 antibody cocktail — but just how well does it protect a vulnerable group?
On the heels of a disappointing performance by Eli Lilly’s antibody targeting the coronavirus, Regeneron is now stepping up with evidence that its antibody cocktail — at the high dose — has a significant impact on slashing viral load in patients most at risk of a dangerous reaction. And they plan to hustle the first cut of the data to regulators, who have already shown an eagerness in getting drugs out to combat Covid-19 as quickly as possible.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.